Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer.
Quintanal-Villalonga A, Kawasaki K, Redin E, Rakhade S, Durani V, Sabet A, Karthaus W, Zaidi S, Zhan Y, Manoj P, Sridhar H, Zhong H, Mello B, Ciampricotti M, Bhanot U, Haffner M, Socci N, Yu H, Chan J, Rudin C. Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer. Journal Of Clinical Oncology 2024, 42: e20105-e20105. DOI: 10.1200/jco.2024.42.16_suppl.e20105.Peer-Reviewed Original ResearchRisk of transformationNE transformationProstatic adenocarcinomaTherapeutic vulnerabilitiesMYC degradationPhase II clinical trialLung tumor modelDelays tumor relapseII clinical trialsTherapy in vivoIn vivo prostateMechanisms of resistanceMYC isoformsNE phenotypeTumor relapseUntreated tumorsNeuroendocrine transformationProstate cancerStemness transcription factorsPotential therapeutic targetTargeted therapyPoor prognosisTumor modelProstateTumor population
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply